Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

108.44
+2.192.06%
Pre-market: 108.17-0.2704-0.25%05:46 EDT
Volume:1.71M
Turnover:184.58M
Market Cap:12.31B
PE:32.06
High:109.63
Open:106.66
Low:105.50
Close:106.25
52wk High:111.15
52wk Low:61.23
Shares:113.50M
Float Shares:112.00M
Volume Ratio:1.42
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.38
EPS(LYR):2.56
ROE:173.67%
ROA:25.49%
PB:85.74
PE(LYR):42.36

Loading ...

Halozyme Therapeutics Slips on $1.05 Bln Convertible Offering Plans

Reuters
·
13 hours ago

Halozyme announces proposed offering of $1.05B of 2033 convertible senior notes

TIPRANKS
·
14 hours ago

Halozyme Plans USD 1.05 Billion Convertible Senior Notes Offering Due 2033

Reuters
·
14 hours ago

Halozyme Therapeutics, - Expects to Use Net Proceeds to Repurchase Outstanding 2027 and 2028 Convertible Notes

THOMSON REUTERS
·
14 hours ago

Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes Due 2033

THOMSON REUTERS
·
14 hours ago

Halozyme CEO Helen Torley Reports Disposal of Common Shares Worth USD 6.5 Million

Reuters
·
Sep 12

Analysts’ Top NA Picks: High Roller Technologies, Inc. (ROLR), Halozyme (HALO)

TIPRANKS
·
Sep 03

H.C. Wainwright views Novartis, Alteogen pact as negative for Halozyme

TIPRANKS
·
Sep 03

Halozyme CEO, CFO to Speak at Wells Fargo Healthcare Conference Fireside Chat

Reuters
·
Sep 02

Barfresh Food Names CEO Delle Coste Interim CFO as Lisa Roger Retires

Reuters
·
Sep 02

Is Halozyme Therapeutics (HALO) Overvalued After Its New Board Appointment?

Simply Wall St.
·
Aug 29

Halozyme Director Dannielle Appelhans Files Initial Beneficial Ownership Statement

Reuters
·
Aug 22

Halozyme CEO Helen Torley Sells USD 4.13 Million in Common Shares

Reuters
·
Aug 20

Halozyme Appoints COUR Pharma CEO Dannielle Appelhans to Board

Reuters
·
Aug 19

Halozyme Appoints Dannielle Appelhans to Its Board of Directors

THOMSON REUTERS
·
Aug 19

Sagtec announces commercial launch of HALO AI Food-Serving Robot

TIPRANKS
·
Aug 18

Movement Alert|Halozyme Therapeutics Rises 5.05% in Regular Trading, Continued Momentum After Q2 Earnings Beat and Analyst Upgrades

Market Focus
·
Aug 18

Halozyme Director Bernadette Connaughton Disposes of 1.626 Shares Worth $167.152,8

Reuters
·
Aug 12

What Halozyme Therapeutics (HALO) Guidance Raise Means For Valuation

Simply Wall St.
·
Aug 11

Movement Alert|Halozyme Therapeutics Rises 16.87% in Regular Trading, Q2 Earnings Massively Beat Expectations with Full-Year Guidance Raised

Market Focus
·
Aug 08